Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity.
暂无分享,去创建一个
I. Pastan | Y. Tsutsumi | Byungkook Lee | R. Kreitman | B. Lee | S. Nagata | M. Onda
[1] J. D. White,et al. Phase I trial of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) in patients with hematologic malignancies. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] I. Pastan,et al. Reduction of the nonspecific animal toxicity of anti-Tac(Fv)-PE38 by mutations in the framework regions of the Fv which lower the isoelectric point. , 1999, Journal of immunology.
[3] M. Stetler-Stevenson,et al. Responses in refractory hairy cell leukemia to a recombinant immunotoxin. , 1999, Blood.
[4] I. Pastan,et al. Hepatotoxicity in cancer patients receiving erb-38, a recombinant immunotoxin that targets the erbB2 receptor. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.
[5] M. Hashida,et al. Targeted delivery and improved therapeutic potential of catalase by chemical modification: combination with superoxide dismutase derivatives. , 1999, The Journal of pharmacology and experimental therapeutics.
[6] I. Pastan,et al. Complete regression of human B‐cell lymphoma xenografts in mice treated with recombinant anti‐CD22 immunotoxin RFB4(dsFv)‐PE38 at doses tolerated by cynomolgus monkeys , 1999, International journal of cancer.
[7] Y. Tsutsumi,et al. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. , 1996, British Journal of Cancer.
[8] Y. Tsutsumi,et al. Molecular design of hybrid tumour necrosis factor alpha with polyethylene glycol increases its anti-tumour potency. , 1995, British Journal of Cancer.
[9] C R King,et al. Improved binding and antitumor activity of a recombinant anti-erbB2 immunotoxin by disulfide stabilization of the Fv fragment. , 1994, The Journal of biological chemistry.
[10] I. Pastan,et al. Antitumor activity and pharmacokinetics in mice of a recombinant immunotoxin containing a disulfide-stabilized Fv fragment. , 1994, Cancer research.
[11] I. Pastan,et al. Pseudomonas exotoxin A mutants. Replacement of surface exposed residues in domain II with cysteine residues that can be modified with polyethylene glycol in a site-specific manner. , 1994, The Journal of biological chemistry.
[12] I. Pastan,et al. Recombinant immunotoxins containing anti-Tac(Fv) and derivatives of Pseudomonas exotoxin produce complete regression in mice of an interleukin-2 receptor-expressing human carcinoma , 1994 .
[13] I. Pastan,et al. Polyethylene glycol-modified chimeric toxin composed of transforming growth factor alpha and Pseudomonas exotoxin. , 1993, Cancer research.
[14] M. Hershfield,et al. IgG antibody response to polyethylene glycol-modified adenosine deaminase in patients with adenosine deaminase deficiency. , 1992, The Journal of clinical investigation.
[15] I. Pastan,et al. B3(Fv)-PE38KDEL, a single-chain immunotoxin that causes complete regression of a human carcinoma in mice. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[16] I. Pastan,et al. Antitumor activity of a transforming growth factor alpha-Pseudomonas exotoxin fusion protein (TGF-alpha-PE40). , 1991, Cancer research.
[17] W. Laird,et al. Chemical modification of recombinant interleukin 2 by polyethylene glycol increases its potency in the murine Meth A sarcoma model. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[18] R. Müller,et al. Surface characteristics and the interaction of colloidal particles with mouse peritoneal macrophages. , 1987, Biomaterials.
[19] F. Davis,et al. Preparation of a polyethylene glycol: superoxide dismutase adduct, and an examination of its blood circulation life and anti-inflammatory activity. , 1980, Research communications in chemical pathology and pharmacology.
[20] R L Blakeley,et al. Ellman's reagent: 5,5'-dithiobis(2-nitrobenzoic acid)--a reexamination. , 1979, Analytical biochemistry.
[21] C. E. Childs. The determination of polyethylene glycol in gamma globulin solutions , 1975 .
[22] T. H. Gronwall. On the Distortion in Conformal Mapping When the Second Coefficient in the Mapping Function Has an Assigned Value. , 1920, Proceedings of the National Academy of Sciences of the United States of America.
[23] T. Kunkel,et al. Efficient site-directed mutagenesis using uracil-containing DNA. , 1991, Methods in enzymology.